There are currently no FDA-approved drugs to treat vitiligo, an autoimmune disease that kills skin pigment cells. But a phase III study of a drug used to treat atopic dermatitis may be the first to get the FDA seal of approval.
COVID-19 researchers focus their studies on antibodies targeting exposed parts of SARS-CoV-2, but in a new study, a group of researchers showed that antibodies targeting proteins inside the virus are just as important for a robust immune response.
The company plans to develop more specialized, antibody-based GPCR drugs to treat a myriad of diseases. They recruited a leader in overseeing successful clinical trials to get the job done.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.